

Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma

Chuanhui Xu,¹ Wouter Plattel,^{1,2} Anke van den Berg,¹ Nele Rüther,³ Xin Huang,¹ Miao Wang,⁴ Debora de Jong,¹ Hans Vos,¹ Gustaaf van Imhoff,² Andreas Viardot,⁵ Peter Möller,³ Sibbrand Poppema,¹ Arjan Diepstra,¹ and Lydia Visser¹

¹Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; ²Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; ³Institute of Pathology, University of Ulm, Ulm, Germany; ⁴Department of Pathology, Capital Medical University, Beijing, China, and ⁵Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany

Citation: Xu C, Plattel W, van den Berg A, Rüther N, Huang X, Wang M, de Jong D, Vos H, van Imhoff G, Viardot A, Möller P, Poppema S, Diepstra A, and Visser L. Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma. *Haematologica* 2012;97(4):572-578. doi:10.3324/haematol.2011.056101

Online Supplementary Table S1. Immunohistochemistry results of c-Met and HGF in cHL cases.

Case	subtype	EBV status	% of c-MET ⁺ HRS cells	% of HGF ⁺ HRS cells
1	LD	+	100	7
2	NS	-	100	5
3	NS	+	100	0
4	NS	-	100	0
5	NS	-	100	0
6	NS	-	100	0
7	NOS	-	100	0
8	NS	+	96	96
9	MC	-	95	10
10	NS	-	95	0
11	NS	-	95	0
12	NS	-	95	0
13	NS	-	90	2
14	MC	+	90	0
15	MC	+	90	0
16	MC	+	90	0
17	NS	-	90	0
18	NS	-	90	0
19	MC	-	90	0
20	NS	+	86	40
21	MC	+	83	6
22	NOS	+	80	0
23	NS	-	80	0
24	NS	-	80	0
25	NS	-	80	0
26	NS	-	80	0
27	NS	-	80	0
28	NS	+	80	N.D.
29	MC	+	80	N.D.
30	NOS	-	80	N.D.
31	NS	-	79	0
32	NS	-	72	0
33	LR	-	70	10
34	NS	-	70	1
35	NS	+	70	0
36	NS	+	70	0
37	NS	-	70	0
38	NS	-	70	0
39	NS	-	70	0
40	MC	-	70	0

continued on next page

continued from previous page

41	NS	-	70	N.D.
42	NOS	-	70	N.D.
43	MC	-	70	N.D.
44	NS	-	60	10
45	NS	-	60	1
46	MC	+	60	0
47	NS	-	60	0
48	NS	-	60	0
49	NS	-	60	0
50	NS	-	60	0
51	NS	-	60	0
52	NS	-	60	0
53	NS	-	60	0
54	NS	-	60	N.D.
55	MC	+	54	10
56	MC	-	50	50
57	MC	-	50	27
58	NS	-	50	2
59	NS	+	50	0
60	MC	+	50	0
61	MC	-	50	0
62	NS	+	50	N.D.
63	NOS	+	50	N.D.
64	NS	-	50	N.D.
65	NS	-	50	N.D.
66	NS	-	50	N.D.
67	NS	-	40	4
68	NOS	-	40	N.D.
69	NS	-	38	0
70	NS	-	38	0
71	NOS	-	33	8
72	NS	-	30	17
73	MC	+	30	0
74	MC	+	30	0
75	NS	-	30	0
76	NS	-	30	0
77	NS	-	30	0
78	NS	-	30	0
79	NS	-	30	0
80	NS	-	30	0
81	NS	+	26	0
82	NS	-	20	5
83	NS	-	20	0
84	NS	-	20	0
85	NS	-	20	0
86	MC	-	20	0
87	NS	+	20	N.D.
88	NS	+	17	0
89	NS	-	17	0
90	NS	-	13	0
91	NS	-	10	5
92	NS	-	10	0
93	NS	-	10	0
94	NS	-	10	0
95	NS	-	10	0
96	MC	-	10	0
97	MC	-	10	0

continued on next page

continued from previous page

98	NS	+	10	N.D.
99	NOS	+	10	N.D.
100	MC	-	10	N.D.
101	MC	-	10	N.D.
102	NS	+	9	0
103	NS	-	8	0
104	NS	-	5	100
105	NS	-	5	30
106	NS	-	5	10
107	NS	+	5	0
108	MC	+	5	0
109	NS	-	5	0
110	NS	-	5	0
111	NS	-	5	0
112	NS	-	5	0
113	NS	+	5	N.D.
114	NS	-	5	N.D.
115	NS	-	5	N.D.
116	NS	-	5	N.D.
117	NS	-	5	N.D.
118	NS	-	5	N.D.
119	MC	-	5	N.D.
120	NS	+	4	0
121	NS	-	2	10
122	NS	-	2	2
123	LR	-	2	0
124	LR	-	1	20
125	NS	+	1	2
126	NS	-	1	0
127	MC	-	1	0
128	NS	-	1	N.D.
129	NS	-	1	N.D.
130	NS	-	0	100
131	NS	+	0	70
132	NS	-	0	20
133	NS	+	0	0
134	MC	+	0	0
135	NS	-	0	0
136	NS	-	0	0
137	NS	-	0	0
138	NS	-	0	0
139	NS	-	0	0
140	NS	-	0	0
141	NS	-	0	0
142	NS	-	0	0
143	NS	-	0	0
144	NOS	-	0	0
145	MC	-	0	0
146	MC	-	0	0
147	MC	-	0	0
148	MC	-	0	0
149	NS	-	0	N.D.
150	NS	-	0	N.D.
151	NS	-	0	N.D.
152	NS	-	0	N.D.
153	NOS	-	0	N.D.

NS: nodular sclerosis; MC: mixed cellularity; LR: lymphocyte rich; LD: lymphocyte depleted; NOS: not otherwise specified; "+" indicates EBV-positive status, "-" indicates EBV-negative status; N.D.: not determined.

Online Supplementary Table S2. c-Met expression by HRS cells in relation to disease parameters, EBV status and HGF expression.

Characteristic	c-Met positive (n =80) N. of patients (%)	c-Met negative (n=73) N. of patients (%)	P value
Median age (range)	28 (8-73)	29 (7-75)	0.49
Male	39 (49)	42 (58)	0.33
Histology subtype			0.58
Nodular sclerosis	54 (68)	56 (77)	
Mixed cellularity	14 (18)	9 (12)	
Lymphocyte rich	1 (1)	2 (3)	
Lymphocyte depleted	1 (1)	-	
cHL, NOS	10 (13)	6 (8)	
Ann Arbor Stage			0.62
I-II	47 (59)	40 (55)	
III-IV	32 (40)	33 (45)	
n.a.	1 (1)	-	
EBV status			0.34
Positive	21 (26)	14 (19)	
Negative	59 (74)	59 (81)	
HGF(n=121)			0.32
positive	4 (6)	6 (11)	
negative	63 (94)	48 (89)	

cHL NOS: classical Hodgkin's lymphoma not otherwise specified; n.a.: not available.

Online Supplementary Table S3. Univariate and multivariate Cox regression analysis for FFTP for c-Met expression and other clinical prognostic factors in the separate cohorts.

German cohort	N.	Univariate		Multivariate			
		HR	95% CI	P	HR	95% CI	P
c-Met expression < 30%	42	4.2	1.4-13.2	0.013	3.9	1.3-12.3	0.018
Stage III/IV	40	4.6	1.5-14.4	0.008	4.5	1.4-13.9	0.010
IPS ≥ 3	22	1.6	0.4-6.4	0.472			
B-symptoms present	45	1.3	0.5-3.6	0.556			
Bulky disease	27	1.5	0.5-4.1	0.451			

Dutch cohort	N.	Univariate		Multivariate			
		HR	95% CI	P	HR	95% CI	P
c-Met expression < 30%	31	8.7	1.1-69.9	0.041			
Stage III/IV	25	1.2	0.3-4.6	0.757			
IPS ≥ 3	13	3.0	0.3-29.2	0.343			
B-symptoms present	25	2.3	0.6-8.7	0.226			
Bulky disease	19	2.5	0.7-9.3	0.182			